Registry for individuals with type 1 diabetes in Canada
Official title: Registry of Individuals With Type 1 Diabetes Living in Canada: The BETTER Registry
Run by Institut de Recherches Cliniques de Montreal · NCT03720197 · Data updated 2026-11-12
This study is gathering information from people with type 1 diabetes in Canada to learn more about their experiences with low blood sugar episodes and how it affects their lives.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Institut de Recherches Cliniques de Montreal Academic / other |
| Locations | 7 sites (Edmonton, Alberta and 6 other locations) |
| Status | Recruiting |
| Started | February 20, 2019 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | February 25, 2025 |
| Trial ID | NCT03720197 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are individuals diagnosed with type 1 diabetes who reside in Canada.
✕Probably not a fit
Patients with type 2 diabetes or gestational diabetes will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to gather comprehensive data on individuals living with type 1 diabetes in Canada, focusing on the frequency and severity of hypoglycemic episodes. Participants will complete questionnaires regarding their experiences with hypoglycemia, including symptoms, fears, and contributing factors such as insulin therapy and nutrition. The study is divided into three phases, with the first phase mandatory for all participants, while the subsequent phases are optional and involve additional data collection, including blood tests and lifestyle assessments. The goal is to create a detailed profile of the type 1 diabetes population in Canada and understand the implications of hypoglycemia.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of hypoglycemia in type 1 diabetes, leading to improved management strategies for patients.
How similar studies have gone: While similar registries have been established, this specific approach focusing on hypoglycemia in type 1 diabetes is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of type 1 diabetes * Living in Canada Exclusion Criteria: * Type 2 diabetes * Gestational diabetes
Where it's running
-
Alberta Diabetes Institute
Edmonton, Alberta, Canada Recruiting -
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada Recruiting -
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada Recruiting -
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada Recruiting -
McGill University Health Centre
Montreal, Quebec, Canada Recruiting -
Centre Hospitalier Universitaire de Québec-Université Laval
Québec, Quebec, Canada Recruiting
Show 1 more location
-
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Remi Rabasa-Lhoret — Institut de Recherches Cliniques de Montreal
- Study coordinator: Virginie Messier
- Email: virginie.messier@ircm.qc.ca
- Phone: 514-987-5500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system
This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.
-
New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery
This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.
-
Oral verapamil in newly diagnosed children and teens with type 1 diabetes
This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.
-
Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches
This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.